CN104958662A - Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof Download PDFInfo
- Publication number
- CN104958662A CN104958662A CN201510470126.XA CN201510470126A CN104958662A CN 104958662 A CN104958662 A CN 104958662A CN 201510470126 A CN201510470126 A CN 201510470126A CN 104958662 A CN104958662 A CN 104958662A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- hyperlipemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 27
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 27
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 208000004930 Fatty Liver Diseases 0.000 title abstract description 8
- 206010019708 Hepatic steatosis Diseases 0.000 title abstract description 8
- 208000010706 fatty liver disease Diseases 0.000 title abstract description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 title abstract description 8
- 241000222336 Ganoderma Species 0.000 claims abstract description 21
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims description 54
- 241000628997 Flos Species 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 241001289529 Fallopia multiflora Species 0.000 abstract description 2
- 240000006079 Schisandra chinensis Species 0.000 abstract description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 240000004307 Citrus medica Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000304432 Sedum sarmentosum Species 0.000 abstract 1
- 241000395105 Stahlianthus involucratus Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 19
- 241000700159 Rattus Species 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 13
- 239000013641 positive control Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicinal composition for treating fatty liver hepatitis combined with hyperlipemia and a preparation method thereof. The traditional Chinese medicinal composition is prepared from the following raw materials: astragalus, coptis chinensis, prepared rehmannia root, polygonum multiflorum, radix bupleuri, sedum sarmentosum, salviae miltiorrhizae, lucid ganoderma, dried tangerine or orange peel, safflower, fleshfingered citron flower, stahlianthus involucratus, semen cassiae, schisandra chinensis and liquorice. The traditional Chinese medicinal composition for treating the fatty liver hepatitis combined with hyperlipemia has obvious curative effect on fatty liver hepatitis combined with hyperlipemia and also has the advantages of small side effect, simple preparation technology and convenience in taking.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of fat hepatitis for the treatment of and merge Chinese medicine composition of hyperlipemia and preparation method thereof.
Background technology
Liver is the requisite vitals that sustain life, it is the substance metabolism center of human body, be responsible for complicated biochemical functions, liver is except dextran albumen, glycogen, lipid and vitamin, also metabolism, deactivation and removing toxic substances are carried out to endogenous and exogenous material matter as red in gallbladder, hormone, medicine, poisonous substance, the biochemical functions of above-mentioned all complexity, all at structure improvement, is carried out in the hepatocyte that function is meticulous.Along with the raising of people's living standard, the sickness rate of fatty liver is more and more higher, and according to statistics, people's abnormal liver function of about 35% is that fatty liver causes.
Fat hepatitis refers to the pathological changes due to overheap fatty in the hepatocyte that a variety of causes causes.The lighter is asymptomatic in its clinical manifestation, and the severe one state of an illness is violent.Generally speaking, fat hepatitis belongs to reversibility disease, and early diagnosis also treatment in time often can recover normal.The morbidity of fatty liver is relevant with following event: drink, fat, diabetes, hyperlipemia, hypertension, high-energy diet, high Animal fat diet, and diet is irregular, and sit is moved less, lethargy, and life is careless and sloppy, family history, inappropriate medication etc.Wherein, insobriety or absorption lipid too much, have become the principal element producing fatty liver.
Hyperlipemia refers to that blood lipid level is too high, directly can cause the disease of some serious harm healths, as atherosclerosis, coronary heart disease, pancreatitis etc.The clinical manifestation of hyperlipemia is the xanthoma of lipid caused by intradermal deposition and the arteriosclerosis of lipid caused by blood vessel endothelium deposition mainly.Therefore under normal conditions, most of patients non-evident sympton and abnormal sign.Many people raise owing to just finding that there is blood plasma lipoprotein level when other reasons carries out blood biochemical inspection.
Although now commercially have much for the Western medicine of fat hepatitis, it is mainly based on lipid lowerers, and because these blood fat reducing Western medicine mostly have potential hepatotoxicity, and action target spot is single.The history of Chinese medicine fat hepatitis is of long standing and well established, and as an importance of modern hepatopathy Comprehensive Treatment, more and more receives publicity in recent years.
Chinese patent application 201410780349.1 discloses a kind of fat hepatitis for the treatment of and merges Chinese medicine composition of hyperlipemia and preparation method thereof, this Chinese medicine composition is prepared from by the raw material of following weight portion: Rhizoma Pinelliae 8-12 part, Rhizoma Iridis Tectori 11-13 part, Fructus Gardeniae 6-8 part, Rhizoma Coptidis 11-15 part, Rhizoma Curcumae Longae 10-12 part, Radix Salviae Miltiorrhizae 6-10 part, Radix Astragali 5-7 part, Herba Artemisiae Scopariae 17-19 part, Radix Paeoniae Alba 10-14 part, Radix Ophiopogonis 4-6 part, Poria 8-10 part, Fructus Schisandrae Chinensis 8-10 part and Radix Glycyrrhizae 10-12 part, this Chinese medicine composition has the effect that treatment fat hepatitis merges hyperlipidemia.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the treatment of fat hepatitis and merging hyperlipemia, this Chinese medicine composition merges in hyperlipemia at treatment fat hepatitis, there is significant curative effect, also have that side effect is little, the advantage such as the simple and taking convenience of preparation technology, in addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use preparation under the prerequisite ensureing curative effect by this Chinese medicine composition.
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight:
Radix Astragali 6-15 part, Rhizoma Coptidis 1-5 part, Radix Rehmanniae Preparata 9-15 part, Radix Polygoni Multiflori 2-5 part, Radix Bupleuri 3-9 part, Herba Sedi 3-15 part, Radix Salviae Miltiorrhizae 9-15 part, Ganoderma 6-12 part, Pericarpium Citri Reticulatae 3-10 part, Flos Carthami 3-9 part, Flos Citri Sarcodactylis 3-6 part, Rhizoma Stahlianthi Involucrati 6-15 part, Semen Cassiae 9-15 part, Fructus Schisandrae Chinensis 1-6 part and Radix Glycyrrhizae 1-10 part.
Further, described Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 6 parts, Rhizoma Coptidis 1 part, Radix Rehmanniae Preparata 9 parts, Radix Polygoni Multiflori 2 parts, Radix Bupleuri 3 parts, Herba Sedi 3 parts, Radix Salviae Miltiorrhizae 9 parts, Ganoderma 6 parts, Pericarpium Citri Reticulatae 3 parts, 3 parts, Flos Carthami, Flos Citri Sarcodactylis 3 parts, Rhizoma Stahlianthi Involucrati 6 parts, Semen Cassiae 9 parts, Fructus Schisandrae Chinensis 1 part and 1 part, Radix Glycyrrhizae.
Further, described Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 15 parts, Rhizoma Coptidis 5 parts, Radix Rehmanniae Preparata 15 parts, Radix Polygoni Multiflori 5 parts, Radix Bupleuri 9 parts, Herba Sedi 15 parts, Radix Salviae Miltiorrhizae 15 parts, Ganoderma 12 parts, Pericarpium Citri Reticulatae 10 parts, 9 parts, Flos Carthami, Flos Citri Sarcodactylis 6 parts, Rhizoma Stahlianthi Involucrati 15 parts, Semen Cassiae 15 parts, Fructus Schisandrae Chinensis 6 parts and 10 parts, Radix Glycyrrhizae.
Further, described Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 10 parts, Rhizoma Coptidis 3 parts, Radix Rehmanniae Preparata 12 parts, Radix Polygoni Multiflori 3 parts, Radix Bupleuri 6 parts, Herba Sedi 9 parts, Radix Salviae Miltiorrhizae 12 parts, Ganoderma 9 parts, Pericarpium Citri Reticulatae 7 parts, 6 parts, Flos Carthami, Flos Citri Sarcodactylis 4 parts, Rhizoma Stahlianthi Involucrati 10 parts, Semen Cassiae 12 parts, Fructus Schisandrae Chinensis 3 parts and 5 parts, Radix Glycyrrhizae.
Further, described Chinese medicine composition is made into tablet, powder, capsule, granule or pill.
Accordingly, the preparation method of described Chinese medicine composition comprises following step:
S1: take the Radix Astragali, Rhizoma Coptidis, Radix Rehmanniae Preparata, Radix Bupleuri, Radix Polygoni Multiflori, Ganoderma, Radix Salviae Miltiorrhizae, Semen Cassiae and Rhizoma Stahlianthi Involucrati, be ground into coarse powder, adds the 6-15 water doubly of coarse powder gross weight, soak 12-24 hour, decoct 1-3 time, each 1-3 hour, filter, retain filtering residue, merging filtrate;
S2: take Herba Sedi, Flos Carthami, Flos Citri Sarcodactylis, Pericarpium Citri Reticulatae, Fructus Schisandrae Chinensis and Radix Glycyrrhizae, be ground into coarse powder, 5-8 ethanol to the alcohol content doubly adding coarse powder gross weight is 60-90%(v/v), leave standstill 24 hours, get supernatant, ethanol is reclaimed in distilling under reduced pressure;
S3: the filtrate of the supernatant of S2 and S1 is merged, be evaporated to the extractum of relative density 1.10-1.25 at 60-75 DEG C, namely obtain Chinese medicine composition of the present invention.
Source, the nature and flavor of the present invention's component used, return through and effect:
The Radix Astragali: this product is the root of leguminous plant Radix Hedysari multijugi; Sweet in the mouth, warm in nature; GUIXIN, lung, spleen, kidney channel; Invigorating QI to consolidate the body surface resistance, diuresis, expelling pus and toxin by strengthening QI, promoting tissue regeneration and ulcer healing.
Rhizoma Coptidis: this product is the dry rhizome of ranunculaceae plant Rhizoma Coptidis; Bitter in the mouth, cold in nature; GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel; Heat clearing and damp drying, eliminating fire and detoxication.
Radix Rehmanniae Preparata: this product is the Preparation process product of Radix Rehmanniae; Sweet in the mouth, slightly warm in nature; Return liver, kidney channel; Nourishing YIN and supplementing blood, beneficial essence fills out marrow.
Radix Polygoni Multiflori: this product is the dried root of polygonum multiflorum thunb; Bitter in the mouth, sweet, puckery, warm in nature; Return liver, the heart, kidney channel; Removing toxic substances, eliminating carbuncle, loosening bowel to relieve constipation.
Radix Bupleuri: this product is the dry root of umbelliferae bupleurum; Bitter in the mouth, cold nature; Hardship, is slightly cold; Reconciling superficies and interior, soothing the liver, yang invigorating.
Herba Sedi: this product is the fresh or dry herb of crassulaceae plants Herba Sedi; Sweet in the mouth, light, cool in nature; Return liver, gallbladder, small intestine meridian; Eliminating damp-heat, removing toxic substances.
Radix Salviae Miltiorrhizae: this product is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae; Bitter in the mouth, cold nature; GUIXIN, Liver Channel; Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness.
Ganoderma: this product is the dry sporophore of On Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. or Ganoderma; Sweet in the mouth, property is put down; GUIXIN, lung, liver, kidney channel; Invigorating QI and tranquilization, relieving cough and asthma.
Pericarpium Citri Reticulatae: this product is the mature peel of rutaceae orange and variety thereof; Acrid in the mouth, hardship, warm in nature; Return spleen, lung meridian; Invigorating the spleen and regulating the stomach, promoting the circulation of QI to alleviate the stagnation in middle-JIAO, lowering the adverse-rising QI and eliminating phlegm.
Flos Carthami: this product is the dried floral of feverfew Flos Carthami; Warm in nature; GUIXIN, Liver Channel; Promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.
Flos Citri Sarcodactylis: this product is flower and the alabastrum of rutaceae Fructus Citri Sarcodactylis; Mildly bitter flavor, slightly warm in nature; Return liver, stomach warp; Depressed liver-energy dispersing and QI regulating, stomach function regulating soon every.
Rhizoma Stahlianthi Involucrati: this product is the tuber of zingiberaceous plant Rhizoma Stahlianthi Involucrati; The micro-hardship of acrid in the mouth, warm in nature; Dissipating blood stasis for subsidence of swelling, promoting blood circulation and hemostasis, promoting the circulation of QI to relieve pain.
Semen Cassiae: this product is the dry mature seed of leguminous plant Semen Cassiae; Sweet in the mouth, hardship, salty, cold nature; Return liver, large intestine channel; Clearing away heat to improve acuity of vision, loosening bowel to relieve constipation.
Fructus Schisandrae Chinensis: this product is the dry mature fruit of magnoliaceae schisandra; Sour in the mouth, sweet, warm in nature; Return lung, the heart, kidney channel; Restrain astringent or styptic treatment for spontaneous sweating, supplementing QI for promoting the production of body fluid, kidney calming.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Compared with prior art, the present invention has following technical advantage:
1, Chinese medicine composition of the present invention merges in hyperlipemia at treatment fat hepatitis, there is significant curative effect, experimental result shows, the present composition obviously can reduce glutamate pyruvate transaminase and the glutamic oxaloacetic transaminase, GOT that fat hepatitis merges hyperlipidemia rats, the liver function of effective adjustment rat, in addition, triglyceride and the serum total cholesterol of rat is also significantly reduced, Be very effective in treatment hyperlipemia.
2, Chinese medicine composition compatibility of the present invention is reasonable, by the synergism between each component, therapeutic effect has more advantage, and in addition, this Chinese medicine composition preparation technology is simple, makes various oral formulations and facilitates patient to take.
3, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, compared with other chemicalses, less to the side effect of patient, and Chinese medicine composition effect of the present invention is comprehensive, and medication effect is better.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1: capsule
The embodiment of the present invention 1 Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 6 parts, Rhizoma Coptidis 1 part, Radix Rehmanniae Preparata 9 parts, Radix Polygoni Multiflori 2 parts, Radix Bupleuri 3 parts, Herba Sedi 3 parts, Radix Salviae Miltiorrhizae 9 parts, Ganoderma 6 parts, Pericarpium Citri Reticulatae 3 parts, 3 parts, Flos Carthami, Flos Citri Sarcodactylis 3 parts, Rhizoma Stahlianthi Involucrati 6 parts, Semen Cassiae 9 parts, Fructus Schisandrae Chinensis 1 part and 1 part, Radix Glycyrrhizae.
Preparation method is as follows:
S1: take the Radix Astragali, Rhizoma Coptidis, Radix Rehmanniae Preparata, Radix Bupleuri, Radix Polygoni Multiflori, Ganoderma, Radix Salviae Miltiorrhizae, Semen Cassiae and Rhizoma Stahlianthi Involucrati, be ground into coarse powder, adds the water of 6 times of coarse powder gross weight, soaks 12 hours, decocts 1 time, each 3 hours, filters, and retains filtering residue, merging filtrate;
S2: take Herba Sedi, Flos Carthami, Flos Citri Sarcodactylis, Pericarpium Citri Reticulatae, Fructus Schisandrae Chinensis and Radix Glycyrrhizae, be ground into coarse powder, 5-8 ethanol to the alcohol content doubly adding coarse powder gross weight is 60%(v/v), leave standstill 24 hours, get supernatant, ethanol is reclaimed in distilling under reduced pressure;
S3: the filtrate of the supernatant of S2 and S1 is merged, be evaporated to the extractum of relative density 1.10 at 60 DEG C;
S4: by the extract dry of S3, be ground into fine powder, fine powder is crossed 80 mesh sieves, remove thick fine powder, add adjuvant wetting agent distilled water and binder syrup, the amount ratio of fine powder and wetting agent, binding agent is 1:0.5:0.5, prepare soft material processed, cross 14 order nylon mesh and granulate, at 70 DEG C, be dried to moisture less than 3%, load in No. 3 capsule shells, obtain the capsule of the embodiment of the present invention 1 Chinese medicine composition.
embodiment 2: capsule
The embodiment of the present invention 2 Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 15 parts, Rhizoma Coptidis 5 parts, Radix Rehmanniae Preparata 15 parts, Radix Polygoni Multiflori 5 parts, Radix Bupleuri 9 parts, Herba Sedi 15 parts, Radix Salviae Miltiorrhizae 15 parts, Ganoderma 12 parts, Pericarpium Citri Reticulatae 10 parts, 9 parts, Flos Carthami, Flos Citri Sarcodactylis 6 parts, Rhizoma Stahlianthi Involucrati 15 parts, Semen Cassiae 15 parts, Fructus Schisandrae Chinensis 6 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3: capsule
The embodiment of the present invention 3 Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 10 parts, Rhizoma Coptidis 3 parts, Radix Rehmanniae Preparata 12 parts, Radix Polygoni Multiflori 3 parts, Radix Bupleuri 6 parts, Herba Sedi 9 parts, Radix Salviae Miltiorrhizae 12 parts, Ganoderma 9 parts, Pericarpium Citri Reticulatae 7 parts, 6 parts, Flos Carthami, Flos Citri Sarcodactylis 4 parts, Rhizoma Stahlianthi Involucrati 10 parts, Semen Cassiae 12 parts, Fructus Schisandrae Chinensis 3 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 4: tablet
The embodiment of the present invention 4 Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 6 parts, Rhizoma Coptidis 1 part, Radix Rehmanniae Preparata 9 parts, Radix Polygoni Multiflori 2 parts, Radix Bupleuri 3 parts, Herba Sedi 3 parts, Radix Salviae Miltiorrhizae 9 parts, Ganoderma 6 parts, Pericarpium Citri Reticulatae 3 parts, 3 parts, Flos Carthami, Flos Citri Sarcodactylis 3 parts, Rhizoma Stahlianthi Involucrati 6 parts, Semen Cassiae 9 parts, Fructus Schisandrae Chinensis 1 part and 1 part, Radix Glycyrrhizae.
Preparation method is as follows:
S1: take the Radix Astragali, Rhizoma Coptidis, Radix Rehmanniae Preparata, Radix Bupleuri, Radix Polygoni Multiflori, Ganoderma, Radix Salviae Miltiorrhizae, Semen Cassiae and Rhizoma Stahlianthi Involucrati, be ground into coarse powder, adds the water of 15 times of coarse powder gross weight, soaks 24 hours, decocts 2 times, each 2 hours, filters, and retains filtering residue, merging filtrate;
S2: take Herba Sedi, Flos Carthami, Flos Citri Sarcodactylis, Pericarpium Citri Reticulatae, Fructus Schisandrae Chinensis and Radix Glycyrrhizae, be ground into coarse powder, 5-8 ethanol to the alcohol content doubly adding coarse powder gross weight is 90%(v/v), leave standstill 24 hours, get supernatant, ethanol is reclaimed in distilling under reduced pressure;
S3: the filtrate of the supernatant of S2 and S1 is merged, be evaporated to the extractum of relative density 1.25 at 75 DEG C;
S4: by the extract dry of S3, be ground into fine powder, the filler Icing Sugar of equivalent is added in fine powder, wetting agent distilled water, disintegrating agent hydroxypropyl starch and lubricant Pulvis Talci, mix homogeneously, obtain soft material processed, soft material processed is put into rotary extrusion type granulator, obtain wet granular, dry under 60 DEG C of conditions, obtain dry granule, cross 20 mesh sieve removing big particles, make uniform particles, add lubricant Pulvis Talci and disintegrating agent hydroxypropyl starch again, wherein granule and lubricant, the amount ratio of disintegrating agent is 1:0.5:1, mix homogeneously, tabletting, obtain tablet, carry out quality inspection, through after the assay was approved, encapsulation, obtain the Chinese medicine composition tablet of the embodiment of the present invention 4.
embodiment 5: tablet
The embodiment of the present invention 5 Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 15 parts, Rhizoma Coptidis 5 parts, Radix Rehmanniae Preparata 15 parts, Radix Polygoni Multiflori 5 parts, Radix Bupleuri 9 parts, Herba Sedi 15 parts, Radix Salviae Miltiorrhizae 15 parts, Ganoderma 12 parts, Pericarpium Citri Reticulatae 10 parts, 9 parts, Flos Carthami, Flos Citri Sarcodactylis 6 parts, Rhizoma Stahlianthi Involucrati 15 parts, Semen Cassiae 15 parts, Fructus Schisandrae Chinensis 6 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is as follows with embodiment 4.
embodiment 6: tablet
The embodiment of the present invention 6 Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 10 parts, Rhizoma Coptidis 3 parts, Radix Rehmanniae Preparata 12 parts, Radix Polygoni Multiflori 3 parts, Radix Bupleuri 6 parts, Herba Sedi 9 parts, Radix Salviae Miltiorrhizae 12 parts, Ganoderma 9 parts, Pericarpium Citri Reticulatae 7 parts, 6 parts, Flos Carthami, Flos Citri Sarcodactylis 4 parts, Rhizoma Stahlianthi Involucrati 10 parts, Semen Cassiae 12 parts, Fructus Schisandrae Chinensis 3 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is as follows with embodiment 4.
embodiment 7: Chinese medicine composition of the present invention merges the therapeutic test of hyperlipidemia rats to fat hepatitis
1, prepare fat hepatitis and merge olive Antihyperlipidemia capsule
Get healthy male SD rat, body weight 0.25-0.3kg, first day gives rats by intraperitoneal injection tetracycline 150mg/kg, after every 6d lumbar injection tetracycline 110mg/kg time, totally 6 times, except lumbar injection tetracycline, every morning 9 gives rat oral gavage 9ml/kgd height lipoprotein emulsion, and the formula of high lipoprotein emulsion is: Adeps Sus domestica 30g, cholesterol 10g, fructose 10g, cholate 2g, distilled water is settled to 100ml.
2, grouping and administration
Get 110 successful rats of modeling, be divided into 11 groups at random, often organize 10, be respectively model group, treatment A group (high, medium and low dosage group), treatment B group (high, medium and low dosage group), treatment C group (high, medium and low dosage group) and positive controls, separately getting 10 healthy rats is blank group, and the concrete administrations of each group is as follows:
Blank group: gavage gives isopyknic normal saline;
Model group: gavage gives equal-volume normal saline;
Treatment A group: gavage gives the capsule that the embodiment of the present invention 1 prepares, and shells, and thin up becomes scattered paste shape, furnishing high dose group (0.8g/kg), middle dosage group (0.5g/kg) and low dose group (0.3g/kg);
Treatment B group: gavage gives the capsule that the embodiment of the present invention 2 prepares, and shells, and thin up becomes scattered paste shape, furnishing high dose group (0.8g/kg), middle dosage group (0.5g/kg) and low dose group (0.3g/kg);
Treatment C group: gavage gives the capsule that the embodiment of the present invention 3 prepares, and shells, and thin up becomes scattered paste shape, furnishing high dose group (0.8g/kg), middle dosage group (0.5g/kg) and low dose group (0.3g/kg);
Positive controls: gavage gives the sunflower liver-protecting tablet of 0.35g/kg, the accurate word Z20003336 of traditional Chinese medicines.
3, testing index
After last administration, pentobarbital sodium anesthetized rat, dissect, abdomen cardinal vein gets hematometry biochemical indicator, gets liver and weighs.
4, result of the test
table 1 Chinese medicine composition of the present invention is on the impact of rat model liver function
Note: compare with model group,
* P< 0.01, compares with positive controls,
★ p< 0.05,
★ ★ p< 0.01.
As shown in Table 1, compared with model group, treatment A group, treatment B group, treatment C group and positive controls can obviously reduce modeling rat glutamate pyruvate transaminase (
p< 0.01) and glutamic oxaloacetic transaminase, GOT (
p< 0.01), Chinese medicine composition high dose group of the present invention have compared with positive controls extremely significant difference (
p< 0.01), visible, Chinese medicine composition of the present invention effectively can regulate glutamate pyruvate transaminase and the glutamic oxaloacetic transaminase, GOT of rat, and the hepatitis for rat has effective therapeutical effect.
table 2 Chinese medicine composition of the present invention is on the impact of rat fat
Note: compare with model group,
* P< 0.01, compares with positive controls,
★ ★ p< 0.01.
As shown in Table 2, compared with model group, treatment A group, treatment B group, treatment C group and positive controls can obviously reduce modeling rat triglyceride (
p< 0.01) and serum total cholesterol (
p< 0.01), but the effect for the treatment of A group, treatment B group and treatment C group is better than positive controls, compared with positive controls, high dose group have extremely significantly difference (
p< 0.01), visible, Chinese medicine composition of the present invention effectively can regulate triglyceride and the serum total cholesterol of rat, and the blood fat for rat has effective regulating action.
5, conclusion
Known by testing, Chinese medicine composition of the present invention has good therapeutic effect in treatment fat hepatitis merging hyperlipemia, can merge the drug use of hyperlipemia as treatment fat hepatitis.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (6)
1. the Chinese medicine composition for the treatment of fat hepatitis and merging hyperlipemia, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Radix Astragali 6-15 part, Rhizoma Coptidis 1-5 part, Radix Rehmanniae Preparata 9-15 part, Radix Polygoni Multiflori 2-5 part, Radix Bupleuri 3-9 part, Herba Sedi 3-15 part, Radix Salviae Miltiorrhizae 9-15 part, Ganoderma 6-12 part, Pericarpium Citri Reticulatae 3-10 part, Flos Carthami 3-9 part, Flos Citri Sarcodactylis 3-6 part, Rhizoma Stahlianthi Involucrati 6-15 part, Semen Cassiae 9-15 part, Fructus Schisandrae Chinensis 1-6 part and Radix Glycyrrhizae 1-10 part.
2. treatment fat hepatitis as claimed in claim 1 merges the Chinese medicine composition of hyperlipemia, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 6 parts, Rhizoma Coptidis 1 part, Radix Rehmanniae Preparata 9 parts, Radix Polygoni Multiflori 2 parts, Radix Bupleuri 3 parts, Herba Sedi 3 parts, Radix Salviae Miltiorrhizae 9 parts, Ganoderma 6 parts, Pericarpium Citri Reticulatae 3 parts, 3 parts, Flos Carthami, Flos Citri Sarcodactylis 3 parts, Rhizoma Stahlianthi Involucrati 6 parts, Semen Cassiae 9 parts, Fructus Schisandrae Chinensis 1 part and 1 part, Radix Glycyrrhizae.
3. treatment fat hepatitis as claimed in claim 1 merges the Chinese medicine composition of hyperlipemia, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 15 parts, Rhizoma Coptidis 5 parts, Radix Rehmanniae Preparata 15 parts, Radix Polygoni Multiflori 5 parts, Radix Bupleuri 9 parts, Herba Sedi 15 parts, Radix Salviae Miltiorrhizae 15 parts, Ganoderma 12 parts, Pericarpium Citri Reticulatae 10 parts, 9 parts, Flos Carthami, Flos Citri Sarcodactylis 6 parts, Rhizoma Stahlianthi Involucrati 15 parts, Semen Cassiae 15 parts, Fructus Schisandrae Chinensis 6 parts and 10 parts, Radix Glycyrrhizae.
4. treatment fat hepatitis as claimed in claim 1 merges the Chinese medicine composition of hyperlipemia, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: the Radix Astragali 10 parts, Rhizoma Coptidis 3 parts, Radix Rehmanniae Preparata 12 parts, Radix Polygoni Multiflori 3 parts, Radix Bupleuri 6 parts, Herba Sedi 9 parts, Radix Salviae Miltiorrhizae 12 parts, Ganoderma 9 parts, Pericarpium Citri Reticulatae 7 parts, 6 parts, Flos Carthami, Flos Citri Sarcodactylis 4 parts, Rhizoma Stahlianthi Involucrati 10 parts, Semen Cassiae 12 parts, Fructus Schisandrae Chinensis 3 parts and 5 parts, Radix Glycyrrhizae.
5. the treatment fat hepatitis as described in as arbitrary in claim 1-4 merges the Chinese medicine composition of hyperlipemia, it is characterized in that: described Chinese medicine composition is made into tablet, powder, capsule, granule or pill.
6. prepare as arbitrary in claim 1-4 as described in treatment fat hepatitis merge the method for Chinese medicine composition of hyperlipemia, it is characterized in that comprising the steps:
S1: take the Radix Astragali, Rhizoma Coptidis, Radix Rehmanniae Preparata, Radix Bupleuri, Radix Polygoni Multiflori, Ganoderma, Radix Salviae Miltiorrhizae, Semen Cassiae and Rhizoma Stahlianthi Involucrati, be ground into coarse powder, adds the 6-15 water doubly of coarse powder gross weight, soak 12-24 hour, decoct 1-3 time, each 1-3 hour, filter, retain filtering residue, merging filtrate;
S2: take Herba Sedi, Flos Carthami, Flos Citri Sarcodactylis, Pericarpium Citri Reticulatae, Fructus Schisandrae Chinensis and Radix Glycyrrhizae, be ground into coarse powder, 5-8 ethanol to the alcohol content doubly adding coarse powder gross weight is 60-90%v/v, and leave standstill 24 hours, get supernatant, ethanol is reclaimed in distilling under reduced pressure;
S3: the filtrate of the supernatant of S2 and S1 is merged, be evaporated to the extractum of relative density 1.10-1.25 at 60-75 DEG C, namely obtain Chinese medicine composition of the present invention.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610338325.XA CN105797034A (en) | 2015-08-04 | 2015-08-04 | Method for preparing traditional Chinese medicinal composition for treating steatohepatitis complicated with hyperlipidemia |
| CN201510470126.XA CN104958662A (en) | 2015-08-04 | 2015-08-04 | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510470126.XA CN104958662A (en) | 2015-08-04 | 2015-08-04 | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610338325.XA Division CN105797034A (en) | 2015-08-04 | 2015-08-04 | Method for preparing traditional Chinese medicinal composition for treating steatohepatitis complicated with hyperlipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104958662A true CN104958662A (en) | 2015-10-07 |
Family
ID=54212863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610338325.XA Withdrawn CN105797034A (en) | 2015-08-04 | 2015-08-04 | Method for preparing traditional Chinese medicinal composition for treating steatohepatitis complicated with hyperlipidemia |
| CN201510470126.XA Withdrawn CN104958662A (en) | 2015-08-04 | 2015-08-04 | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610338325.XA Withdrawn CN105797034A (en) | 2015-08-04 | 2015-08-04 | Method for preparing traditional Chinese medicinal composition for treating steatohepatitis complicated with hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105797034A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110064005A (en) * | 2019-06-14 | 2019-07-30 | 西安博爱制药有限责任公司 | A kind of preparation method for treating the Wuling Pill of chronic hepatitis for improving liver function |
| CN110859891A (en) * | 2019-12-10 | 2020-03-06 | 河北东府文化交流股份有限公司 | Sanqing tea |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085330A (en) * | 2007-06-08 | 2007-12-12 | 济南新境界企业管理咨询有限公司 | Oral administration traditional Chinese medicine composition for treating hyperlipoidemia |
| CN101125185A (en) * | 2006-08-16 | 2008-02-20 | 孙瑞山 | Traditional Chinese medicine for treating fatty liver |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552579B (en) * | 2012-01-21 | 2014-11-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition for treating hyperlipemia fatty liver, as well as preparation method, quality detection method and application thereof |
-
2015
- 2015-08-04 CN CN201610338325.XA patent/CN105797034A/en not_active Withdrawn
- 2015-08-04 CN CN201510470126.XA patent/CN104958662A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125185A (en) * | 2006-08-16 | 2008-02-20 | 孙瑞山 | Traditional Chinese medicine for treating fatty liver |
| CN101085330A (en) * | 2007-06-08 | 2007-12-12 | 济南新境界企业管理咨询有限公司 | Oral administration traditional Chinese medicine composition for treating hyperlipoidemia |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110064005A (en) * | 2019-06-14 | 2019-07-30 | 西安博爱制药有限责任公司 | A kind of preparation method for treating the Wuling Pill of chronic hepatitis for improving liver function |
| CN110859891A (en) * | 2019-12-10 | 2020-03-06 | 河北东府文化交流股份有限公司 | Sanqing tea |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105797034A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068625B (en) | Traditional Chinese medicinal composition for reducing blood sugar and blood pressure and preparation method thereof | |
| CN101347612B (en) | Compound medicament for treating common cold cough and acute/chronic bronchitis, and preparation method thereof | |
| CN102488850B (en) | Traditional Chinese medicinal composition for treating alcoholic fatty liver and preparation method thereof | |
| CN1951481A (en) | Medicament for treating cerebral thrombosis | |
| CN1471953A (en) | Medicinal plant composition for treating AIDS patient | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN102488743B (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN104524159A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands | |
| CN108042766A (en) | A kind of Bushen Tongluo supports brain cream and preparation method thereof | |
| CN104958662A (en) | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
| CN104644967A (en) | Pharmaceutical composition for treating I-type diabetes and application thereof | |
| CN104225425A (en) | Chinese herbal preparation for enhancing immunity, improving sleep and preventing cardio-cerebrovascular disease, and preparation method thereof | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN111000969A (en) | Pharmaceutical composition for treating simple obesity and preparation method thereof | |
| CN1075727C (en) | Shentong capsule and preparing method thereof | |
| CN104189770A (en) | Pharmaceutical composition for treating tuberculous pleuritis and preparation method thereof | |
| CN1044198C (en) | Prescription of weifuyuan capsule and its preparation method | |
| CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
| CN108186874B (en) | A Chinese medicinal composition for treating diabetes | |
| CN106729368B (en) | Medicine composition for treating hypertension and preparation method and application thereof | |
| CN105709193A (en) | Artemisia argyi Levl-containing traditional Chinese medicine preparation for treating chronic enteritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yu Jiao Inventor after: Li Yuhua Inventor before: Liu Xuejian |
|
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151007 |